Codex DNA, Inc.: directors' dealings · United States · SEC (Form 4)

About Codex DNA, Inc.

Codex DNA, Inc. is a United States-based biotechnology company listed on the Nasdaq Global Select Market under the ticker DNAY. The company operates in the synthetic biology tools segment and focuses on enabling laboratory customers to design, build, and test DNA and mRNA more quickly through automated workflows. Its core value proposition is built around the BioXp platform family, together with associated kits, reagents, and workflow software. In practical terms, Codex DNA sells instruments and consumables that help research teams accelerate molecular biology tasks that traditionally require more manual labor and longer turnaround times. The company was incorporated in Delaware in March 2011, originally as Synthetic Genomics Solution, Inc. It later became SGI-DNA and adopted the Codex DNA name in 2020. Codex DNA went public on Nasdaq in June 2021, and its principal headquarters have been in San Diego, California, in the United States. That location is relevant strategically, as San Diego is one of the major life-sciences hubs in the U.S. and provides access to talent, customers, and manufacturing partners. From a business-model standpoint, Codex DNA combines capital equipment sales with recurring revenue from kits and reagents. Its product suite centers on the BioXp 3250 system and related BioXp kits and benchtop reagent products. The company has described BioXp as a fully automated benchtop solution for synthetic biology workflows, helping users generate genes, clones, variant libraries, and mRNA faster and with less hands-on time. That positioning matters because it can improve workflow standardization and productivity for customers in pharmaceutical research and academic settings. Codex DNA serves a specialized customer base that includes biopharmaceutical companies, academic research institutions, government labs, contract research organizations, and synthetic biology companies. Its end markets include personalized medicine, biologics drug discovery, vaccine development, genome editing, and cell and gene therapy. Competitively, the company sits in a niche market where differentiation depends on automation, ease of use, throughput, and the ability to integrate hardware with consumables and software. It faces competition from broader laboratory instrumentation companies, DNA synthesis providers, and in-house solutions used by large pharma organizations. Publicly available SEC disclosures indicate that Codex DNA has built an installed base of BioXp systems globally and has launched multiple kits and related products over time. The company has also expanded its commercial footprint through product development and customer outreach. More recently, investors have continued to monitor the company through SEC filings, including insider transaction disclosures on Form 4, which can be relevant as a sentiment indicator but should not be read as a substitute for operational fundamentals. Overall, Codex DNA is best viewed as a small-cap, innovation-driven life-sciences tools company on Nasdaq in the United States. Its upside depends on broader adoption of synthetic biology automation, sustained product development, and the ability to convert a technically differentiated platform into durable revenue growth and improving operating leverage.